Alpha-GPC (alpha-glycerylphosphorylcholine) is a choline compound that crosses the blood-brain barrier and raises brain acetylcholine levels. Most people take it for one of two reasons: sharper focus and mental performance before deep work, or a pre-workout bump in power output and growth hormone.
Mechanistically, Alpha-GPC donates its choline head group to make acetylcholine, the neurotransmitter that drives muscle contraction, attention, and memory formation. Unlike choline bitartrate, it actually gets into the brain in meaningful amounts, which is why it shows up in nootropic stacks and not just as a generic choline source. Acetylcholine also sits at the where the nerve meets the muscle, which is why Alpha-GPC has a legitimate claim on power output, not just cognition.
Acutely, within 60-90 minutes of a 300-600 mg dose, most people notice a subtle lift in focus, mental sharpness, and the kind of clean, non-stimulated cognitive engagement that makes demanding tasks feel less effortful. Unlike caffeine, there's no racing heart or jitter. On training days, expect a slightly stronger mind-muscle connection and, anecdotally, better performance on compound lifts where neuromuscular coordination matters.
The growth hormone pulse after resistance training is transient and won’t contribute in any meaningful way.
In healthy high-performers, the effect is modest and sometimes within the noise of day-to-day variation.
Some people feel nothing. Try it 3-5 times at 300-600 mg, 60 minutes before a demanding task, and compare to how you normally feel on similar tasks. If you notice nothing across several trials, it's probably not doing much for you.
Short-term side effects are mild and uncommon: heartburn, headache, nausea, mild dizziness, and occasionally vivid dreams or insomnia if dosed late in the day. Human trials up to 1,200 mg/day for 6 months have not reported serious adverse events.
Cardiovascular health: Alpha-GPC is a choline compound, and gut bacteria convert choline to TMAO (trimethylamine-N-oxide), a metabolite linked to atherosclerosis, endothelial dysfunction, and stroke risk in humans. Mouse feeding studies show Alpha-GPC directly promotes atherosclerotic lesion development. Human data is messier, a 2021 Korean cohort study of 12 million adults found elevated stroke risk in long-term Alpha-GPC users with a dose-response pattern, while a 2025 follow-up in people with mild cognitive impairment found the opposite. The signal isn't settled, but the mechanism is real.
Direct feeding studies in mice show Alpha-GPC significantly raises plasma TMAO and accelerates atherosclerotic lesion development through multiple pathways, including direct endothelial MAPK and NF-κB activation independent of TMAO. Alpha-GPC also raised TMAO more than phosphatidylcholine in rodent comparisons, suggesting the free-choline-like behavior of Alpha-GPC in the gut is the problem.